CeriBell (CBLL) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Company Overview and Market Opportunity

• Introduced a novel brain monitoring platform combining easy-to-use hardware and AI-driven software for seizure detection in acute care settings.

• Achieved a $69 million annual revenue run rate in Q3 2024, with 46% year-on-year growth and over 500 active U.S. hospital accounts.

• Gross margin reached 86% for FY 2024 YTD, supported by a recurring revenue model based on SaaS and disposable headbands.

• U.S. annual addressable market exceeds $2 billion, with expansion potential into delirium, stroke, and other indications.

• Business model features recurring revenue from SaaS and disposables, with high customer retention and no capital sales.

Clinical Need and Solution

• Seizures in ICU are common, often undetectable without EEG, and delayed treatment significantly increases mortality and morbidity.

• Early EEG is critical; guidelines recommend rapid setup, but conventional EEG is slow and resource-intensive.

• The platform enables setup in five minutes by non-specialists, with AI providing real-time, continuous monitoring and alerts.

• Proprietary AI-powered Clarity algorithm analyzes EEG every 10 seconds, providing actionable insights and bedside alerts.

• Clinical evidence shows reduced ICU stay, faster EEG access, and improved patient outcomes compared to conventional EEG.

Clinical and Economic Impact

• SAFER-EEG study showed reduced ICU length of stay by 4.1 days and improved neurological outcomes.

• Use of the platform led to reduced over-administration of anti-seizure medication and fewer unnecessary patient transfers.

• 94% of transfers that would have been made were avoided, and 53% of cases saw changed clinical management.

• Over 35 peer-reviewed publications and 75+ abstracts support clinical and economic benefits.